Development

Gilead Sciences and Arcus Biosciences have expanded their research collaboration to include inflammatory diseases in addition to oncology.

Webinar Date/Time: Wed, Jun 14, 2023 11:00 AM EDT

Under the collaboration, BiOneCure Therapeutics and Nanjing Leads Biolabs intend to develop a range of innovative antibody-drug conjugates for treating solid tumors.

Webinar Date/Time: Wednesday May 31, 2023 at 11am EDT | 10am CDT | 8am PDT

Webinar Date/Time: Tuesday June 13, 2023 at 11 am EDT | 4pm BST | 5pm CEST

Dr. Ulrike Lemke, Head of Sterile Fill Finish at Recipharm, sat down with Grant Playter, associate editor, to discuss drug delivery forms.

Webinar Date/Time: Wed, May 24, 2023 2:00 PM EDT

Vibha Jawa, executive director at Bristol Myers Squibb, discusses foreign epitopes recognition from what should be fully human antibody therapies.

The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.

The use of smart tools in early drug discovery can have an impact on downstream phases of drug development.

The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges.

Competition in the organ-on-a-chip market increases as NETRI enters the arena.

Process control is essential for using continuous hot-melt extrusion to enhance solubility.

Digital transformation to the Pharma 4.0 paradigm moves forward in process development and clinical and commercial manufacturing.

Roger Viney, chief commercial officer at ICE Pharma, discusses the history and current use of bile acid therapeutics.

Webinar Date/Time: Friday, May 19, 2023 at 11am EDT| 10am CDT | 8am PDT

Aspect Biosystems and Novo Nordisk A/S have announced a collaboration, development, and license agreement to develop bioprinted tissue therapeutics.

The leaked study summary found that Carvykti (ciltacabtagene autoleucel) reduced disease progression by 74%.

BioChain has reached partnerships with NanoString and 10x Genomics to extend its spatial multiomics services.

Rafael Antunes, vice-president of Business Development Europe at Aurisco, speaks about his company's recent efforts in the field of oligonucleotides, its partnership with Cytiva, and its broader sustainability efforts.

Gregor Kawaletz, head of Oral Solid Dose Business Unit at Recipharm, discusses the immediate future of oral biologics

Moderna and Merck reported that a combination therapy involving pembrolizumab and an mRNA demonstrated a 44% reduction in recurrence or death in cancer patients compared to non-combination treatments.

Lipids aren’t the only important ingredients influencing stability and in vivo performance.

The recent success of mRNA vaccines has opened the door for further and future development of nucleic acid-based therapies.

Actions combatting the next pandemic must be diverse, reliable, and sustainable.

Unique solutions are required to protect inherently unstable messenger RNA.

This article reviews a range of techniques available for separative analysis of mRNA therapeutics, their associated impurities, and delivery vehicles.

Considerable efforts have been made over the years to resolve the key issues of stability and delivery of RNA-based therapeutics.

The complexity of the RNA production process creates challenges.

FDA has granted fast track designation to Caribou Biosciences for its allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.